Adeno-associated virus (AAV) is a widely used gene therapy vector for treating hereditary retinal diseases, which are caused by mutations in genes critical for retinal function, such as RPE65, CEP290, ...

Unity Software Inc. U is scheduled to release second-quarter 2025 results on Wednesday. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 50%. U’s Q2 Estimate ...

Texas, USA-based Nanoscope Therapeutics has recently submitted a rolling biologics license application (BLA) to the Food and ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS ...

Ransomware experts Halcyon and Sophos are to pool their expertise in ransomware, working together to enhance data- and ...

At Black Hat USA 2025, CrowdStrike warns that cyber criminals and nation-states are weaponising GenAI to scale attacks and ...

The company announced a pending acquisition of American Homestar for approximately $184 million in cash, expected to close early in the third quarter, with anticipated cost reductions and product and ...

Popiel shared an insider’s view of how businesses are responding to tariffs with Colorado Matters senior host, Ryan Warner. Popiel is also on the board of directors of Denver’s World Trade Center.

DeepTempo, a pioneer in behavioral threat detection powered by deep learning, will be on the ground at Black Hat USA 2025, DEF CON 33, and BSides Las Vegas. As the cybersecurity landscape evolves with ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma ...

TexAmericas Center, which owns and operates the third ranked mixed-use industrial park in the U.S., announced July 29 that ...

This study provides novel and convincing evidence that both dopamine D1 and D2 expressing neurons in the nucleus accumbens shell are crucial for the expression of cue-guided action selection, a ...